SCHEMBL3762068

SCHEMBL3762068

CC(C)(C)OC(=O)C(NC(=O)Cc1[c]cccc1)N1CCCC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.43
GPR119 Q8TDV5 3/20 0.37
ALDH1A1 P00352 3/20 0.34
KMT2A Q03164 2/20 0.34
TSHR P16473 2/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
CNR2 P34972 2/20 0.34
CYP1A2 P05177 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
YAP1 P46937 1/20 0.33
UGCG Q16739 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16161887 0.81 CTSL (0.42) CTSLGPR119MAPTLMNACNR2
SCHEMBL11286029 0.70 MTNR1A (0.40) GPR119ALDH1A1KMT2ATSHRHTT
SCHEMBL3757711 0.68 NFKB1 (0.36) GPR119KMT2AMEN1
SCHEMBL3751891 0.67 ALDH1A1 (0.43) ALDH1A1KMT2AMAPTSMN1; SMN2MEN1
SCHEMBL3756704 0.67 HTT (0.41) ALDH1A1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL27152691 0.66 CYP1A2 (0.47) CTSLALDH1A1MAPTHTTSMN1; SMN2
SCHEMBL3764785 0.65 CTSL (0.39) CTSLALDH1A1KMT2ATSHRMAPT
SCHEMBL2577621 0.65 SLC6A3 (0.38) ALDH1A1KMT2ASMN1; SMN2MEN1LMNA
SCHEMBL3762071 0.65 MEN1 (0.36) CTSLGPR119KMT2AMEN1
SCHEMBL1861965 0.65 NQO2 (0.46) KMT2ATSHRMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA CTSL 4214/4885GPR119 1143/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.